Thermo Fisher Scientific (NYSE:TMO) Updates FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 24.220-24.800 for the period, compared to the consensus estimate of 24.640. The company issued revenue guidance of $46.3 billion-$47.2 billion, compared to the consensus revenue estimate of $46.5 billion.

Analysts Set New Price Targets

TMO has been the topic of several research reports. UBS Group raised their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a research report on Sunday, December 7th. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $580.00 to $660.00 in a report on Thursday, December 11th. Finally, Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $626.79.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $593.16 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $222.86 billion, a PE ratio of 34.27, a price-to-earnings-growth ratio of 3.99 and a beta of 0.91. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $643.99. The stock’s 50-day simple moving average is $594.14 and its 200 day simple moving average is $536.01.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating analysts’ consensus estimates of $6.44 by $0.13. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. On average, analysts anticipate that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific declared that its board has initiated a stock buyback plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, COO Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the completion of the transaction, the chief operating officer owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at $11,238,600. This represents a 36.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 124,517 shares of company stock valued at $72,363,568 in the last quarter. 0.33% of the stock is currently owned by company insiders.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $6.57 vs. consensus ~$6.44 and revenue $12.21B vs. ~$11.95B, showing 7% sales growth and reinforcing demand from pharma and life‑sciences customers. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management disclosed potential EPS upside from the Clario deal, which could be accretive and support longer‑term earnings growth if integration goes as planned. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
• Positive Sentiment: Some analysts remain bullish — William Blair maintained a Buy on TMO, citing resilient organic growth and stabilizing end markets. Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End-Markets Support Sustained Buy Rating
• Neutral Sentiment: Investor presentation and earnings call provide detail on segment performance, but no near-term catalytic change was signaled beyond the guidance update. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: FY2026 guidance came in cautious: EPS $24.220–24.800 (vs. consensus ~24.64) and revenue $46.3B–$47.2B (vs. consensus ~46.5B), implying only 4%–6% growth and modest organic demand — investors focused on the conservative tone. Thermo Fisher stock slides on cautious profit guidance
• Negative Sentiment: Management signaled margin pressure and cautious profit expectations for 2026, which pressured the stock despite the Q4 beat. Thermo Fisher slips after issuing 2026 outlook (update)

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $170,000. Raymond James Financial Inc. grew its position in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.